Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Chaplin

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Vaccine|December 1, 2009
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNEAlfred von Krempelhuber, Jens Vollmar, Rolf Pokorny, et al.
Journal of Virology|July 30, 2010
Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in miceChristine Meisinger-Henschel, Michaela Späth, Susanne Lukassen, et al.
Journal of Virology|October 10, 2014
Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responsesMichael Wolferstätter, Marc Schweneker, Michaela Späth, et al.
The Journal of Infectious Diseases|December 11, 2012
Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjectsRichard N Greenberg, Edgar Turner Overton, David W Haas, et al.
The Journal of General Virology|August 15, 2003
Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopesSylvie Corbet, Henrik Vedel Nielsen, Lasse Vinner, et al.
Plos One|April 17, 2015
Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study populationEva-Maria Zitzmann-Roth, Frank von Sonnenburg, Stephan de la Motte, et al.
Journal for Immunotherapy of Cancer|February 13, 2021
Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memoryMaria Hinterberger, Raphael Giessel, Giovanna Fiore, et al.
The Journal of Infectious Diseases|November 21, 2022
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox VaccinesHeiko Ilchmann, Nathaly Samy, Daniela Reichhardt, et al.
Vaccine|February 15, 2020
Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trialNathaly Samy, Daniela Reichhardt, Darja Schmidt, et al.
Vaccine|December 13, 2005
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccineJens Vollmar, Nathaly Arndtz, Karl M Eckl, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Vaccine|December 1, 2009
A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNEAlfred von Krempelhuber, Jens Vollmar, Rolf Pokorny, et al.
Journal of Virology|July 30, 2010
Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in miceChristine Meisinger-Henschel, Michaela Späth, Susanne Lukassen, et al.
Journal of Virology|October 10, 2014
Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responsesMichael Wolferstätter, Marc Schweneker, Michaela Späth, et al.
The Journal of Infectious Diseases|December 11, 2012
Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjectsRichard N Greenberg, Edgar Turner Overton, David W Haas, et al.
The Journal of General Virology|August 15, 2003
Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopesSylvie Corbet, Henrik Vedel Nielsen, Lasse Vinner, et al.
Plos One|April 17, 2015
Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study populationEva-Maria Zitzmann-Roth, Frank von Sonnenburg, Stephan de la Motte, et al.
Journal for Immunotherapy of Cancer|February 13, 2021
Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memoryMaria Hinterberger, Raphael Giessel, Giovanna Fiore, et al.
The Journal of Infectious Diseases|November 21, 2022
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox VaccinesHeiko Ilchmann, Nathaly Samy, Daniela Reichhardt, et al.
Vaccine|February 15, 2020
Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV vaccine: A randomized phase I clinical trialNathaly Samy, Daniela Reichhardt, Darja Schmidt, et al.
Vaccine|December 13, 2005
Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccineJens Vollmar, Nathaly Arndtz, Karl M Eckl, et al.
Pageof 6